Regular treatment with formoterol and inhaled steroids for chronic asthma: Serious adverse events

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Cates, Christopher J ^a   Jaeschke, Roman ^b   Schmidt, Stefanie ^c   Ferrer, Montse ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FORMOTEROL; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ETHANOLAMINE DERIVATIVE;

ADVERSE DRUG REACTION; ASTHMA; CAUSE OF DEATH; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG FATALITY; HUMAN; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADOLESCENT; ADULT; CHILD; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; ETHANOLAMINES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84885784892     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006924.pub3     Document Type: Review

References (247)

1. AstraZeneca. A comparison of SYMBICORT pMDI with budesonide HFA pMDI in African American subjects with asthma. http://www.astrazenecaclinicaltrials.com/ ?mshost800325/content/clinical-trials/resources/pdf/ D5896C00022 (accessed 15 October 2012).
2. Brown RW, O'Brien CD, Martin UJ, Uryniak T, Lampl KL. Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial. Journal of Allergy and Clinical Immunology 2012;130(2):362-7e9. [1097-6825: (Electronic)]
3. Brown RW, Uryniak T, Lampl KL. Long-term safety of budesonide/formoterol pressurized metered-dose inhaler (PMDI) and budesonide PMDI In African-American patients with asthma: asthma exacerbations and adverse events [Abstract]. American Journal of Respiratory and Critical Care Medicine 2011; Vol. 183, issue Meeting Abstracts:A1294.
4. AstraZeneca. Symbicort high dose once daily in mild to moderate asthmatic patients (SD-039-0666). http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0666.pdf (accessed 26 November 2008).
5. Buhl R, Creemers JP, Vondra V, Martelli NA, Naya IP, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respiratory Medicine. 2003/04/16 2003; Vol. 97, issue 4: 323-30. [0954-6111: (Print)]
6. Buhl R, Creemers JPHM, Vondra V,Martelli NA. Improved and maintained asthma control with once-daily budesonide/ formoterol single inhaler in mild-to-moderate persistent asthma. European Respiratory Journal 2001;18(Suppl 33): 21s.
7. Buhl R, Creemers JPHM, Vondra V, Martelli NA. Once daily symbicort (budesonide/eformoterol in a single inhaler) is effective in moderate-persistent asthma. Thorax 2001;56 (Suppl 3):iii62.
8. Buhl R, Creemers JPHM, Vondra V, Martelli NA. Oncedaily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma. European Respiratory Journal 2001;18(Suppl 33):21s.
9. Buhl R, Creemers JPHM, Vondra V, Martelli NA. Symbicort® budesonide and formoterol in a single inhaler administered once daily is effective in mild to moderate asthma. Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA 2001: D31.
10. Chuchalin A G, Svensson K, Stahl E, Ovcharenko S I, Goriachkina L A, Sidorenko I V, et al. A health-related quality-of-life comparison of formoterol (Oxis) Turbuhaler plus budesonide (Pulmicort) Turbuhaler with budesonide Turbuhaler alone and noncorticosteroid treatment in asthma: a randomized clinical study in Russia. Respiration 2002;69(5):427-33.
11. Chuchalin A, Stahl E, Svensson K, Ovcharenko S, Goriachkina L, Sidorenko I, et al. Formoterol (oxis(r)) turbuhaler(r) plus budesonide turbuhaler(r) and budesonide alone improve health-related quality of life vs non-steroid therapy in mild to moderate asthma in Russia [abstract]. American Journal of Respiratory and Critical Care Medicine 2001;163(5 Suppl):A506.
12. Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN. Formoterol Oxis® Turbuhaler® plus budesonide turbuhaler® is more effective than current non-steroid therapy and budesonide alone in mild to moderate asthma in Russia. Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA.
13. Chuchalin AG, Ovcharenko SI, Goriachkina LA, Sidorenko IV, Tsoi AN, Epoch Study G. The safety and efficacy of formoterol OxisRTurbuhalerR plus budesonide PulmicortRTurbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia. International Journal of Clinical Practice 2002; Vol. 56, issue 1:15-20.
14. AstraZeneca. SD-039-0716. A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of SYMBICORT® pMDI (80/4.5 μg) versus its monoproducts (budesonide andformoterol) in children (=6 years of age) and adults with asthma SPRUCE 80/ 4.5. http://www.astrazenecaclinicaltrials.com/sites/133/ imagebank/typeArticleparam528362/SD-039-0716.pdf (accessed November 2008).
15. Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS. Twelve-week, randomized, placebocontrolled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics 2007; Vol. 29, issue 5:823-43.
16. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L. Patient satisfaction with budesonide and formoterol in one pressurized metered-dose inhaler in adults with mild to moderate persistent asthma [Abstract]. American Thoracic Society International Conference; May 18-23, 2007; San Francisco, California, USA. Poster #928.
17. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Current Medical Research and Opinion 2008; Vol. 24, issue 3:879-94.
18. AstraZeneca. A randomized, double-blind, activecontrolled, parallel-group, single dummy, multicenter, 12 week study to assess the efficacy and safety of SYMBICORT® pMDI 160/4.5 μg × 2 actuations once-daily (qd) compared to SYMBICORT pMDI 80/ 4.5 μg × 2 actuations qd, SYMBICORT pMDI80/4.5 μg × 2 actuations twice-daily (bid) and to budesonide pMDI 160 μg × 2 actuations qd in asthmatic subjects 12 years of age and older. [D5896C00001]. http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/typeArticleparam528362/D5896C00001.pdf (accessed 11 November 2008).
19. Kerwin EM, Oppenheimer JJ, LaForce C, Miller CJ, O'Dowd L, Goldman M. Effects on pulmonary function of once-daily (qd) budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) in adults and adolescents with asthma previously stable with twicedaily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology 2008;121(2 Suppl 1):S152-3.
20. LaForce C, Kerwin EM, Oppenheimer JJ, Miller CJ, Vervaet P, O'Dowd L, et al. Safety of once-daily (qd) budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) in adults and adolescents with asthma previously stable With twice-daily (bid) budesonide/formoterol pMDI. Journal of Allergy and Clinical Immunology 2008;121(2 Suppl 1):S153.
21. Oppenheimer JJ, Kerwin EM, LaForce C, Miller CJ, O'Dowd L, Goldman M. Asthma control with oncedaily (qd) budesonide/formoterol pressurized metereddose inhaler (pMDI) in adults and adolescents with asthma previously stable with twice-daily (bid) budesonide/ formoterol pMDI. Journal of Allergy and Clinical Immunology 2008;121(2 Suppl 1):S8.
22. AstraZeneca. Efficacy and safety of Symbicort® (budesonide/ formoterol) 1280/36 mcg daily delivered dose compared to Pulmicort® (budesonide) 1600 mcg metered dose and Pulmicort (budesonide) 1600 mcg metered dose plus Oxis® (formoterol) 36 mcg delivered dose all delivered via Turbuhaler® in steroid-using asthmatic adolescents and adults: a double-blind, double-dummy, randomized, parallel group, phase III, multicentre study. (SD-039- 0689). http://www.astrazenecaclinicaltrials.com/sites/133/ imagebank/typeArticleparam528362/SD-039-0689.pdfs (accessed 26 November 2008).
23. Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, et al. Efficacy and safety of high-dose budesonide/ formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma. Respirology 2006; Vol. 11, issue 3:276-86.
24. Jenkins C, Kolarikova R, Kuna P, Caillaud D, Sanchis J, Popp W, et al. Symbicort® turbuhaler® offers an effective and well tolerated treatment for patients with moderate to severe asthma [abstract] American Thoracic Society 99th International Conference; 2003 May 16-21; Seattle. Seattle, 2003:D034 Poster C37.
25. AstraZeneca. Symbicort low dose once daily in mild to moderate asthmatic patients (SD-039-0665). http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0665.pdf (accessed 26 November 2008).
26. Kuna P, Chuchalin A, Ringdal N, De la Padilla EA, Black P, Lindqvist A, et al. Low-dose single-inhaler budesonide/ formoterol administered once daily is effective in mildpersistent asthma. European Respiratory Journal 2001;18 (Suppl 33):158s.
27. Kuna P, Creemers J, Vondra V, Black PN, Lindqvist A, Nihlen U, et al. Once-daily dosing with budesonide/ formoterol compared with twice-daily budesonide/ formoterol and once-daily budesonide in adults with mild to moderate asthma. Respiratory Medicine 2006; Vol. 100, issue 12:2151-9.
28. Meltzer E, Nolte H, LaForce C. Efficacy and safety of combined mometasone furoate/formoterol 100/10?g twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids [Abstract]. European Respiratory Society Annual Congress; September 18-22, 2010; Barcelona, Spain. Poster 1203.
29. Meltzer E, Nolte H, Laforce C. Low-dose mometasone furoate/formoterol therapy: safety and tolerability findings from a study investigating the effects of a new combination treatment for asthma [Abstract]. Annals of Allergy, Asthma, and Immunology 2009:A66.
30. Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. European Respiratory Journal. 2011/08/11 2012; Vol. 39, issue 2: 279-89. [1399-3003: (Electronic)]
31. Meltzer EO, Nolte H, LaForce C. Treatment of moderate asthma with mometasone furoate and formoterol (MF/F) 100/10 1/4g twice-daily administered via a pressurized metered-dose inhaler: efficacy and safety characteristics in subjects 12 years of age and older [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010; Vol. 181, issue Meeting Abstracts:A5661.
32. AstraZeneca. A randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort pMDI (budesonide/formoterol 160/ 4.5 mcg 2 actuations b.i.d., delivered dose) with that of Pulmicort pMDI (budesonide 200 mcg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler (budesonide/ formoterol 160/4.5 mcg 2 inhalations b.i.d., delivered dose) in adolescents and adults with asthma. http:// www.astrazenecaclinicaltrials.com/search/?itemId=8574676 (accessed 26 November 2008).
33. Morice AH, Hochmuth L, Puterman A, Artheden L, Beckman O. Comparable safety of a novel budesonide/ formoterol pMDI versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma [Abstract]. Journal of Allergy Clinical Immunology 2005; Vol. 115, issue 2 Suppl:S3.
34. Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. International Journal of Clinical Practice. 2007/09/25 2007; Vol. 61, issue 11:1874-83. [1368-5031: (Print)]
35. AstraZeneca. A 12-week randomised, double-blind, parallel-group, multicentre phase-III study to compare the efficacy and safety of Symbicort® pMDI (budesonide/ formoterol 80/4.5 μg 2 actuations b.i.d., delivered dose) with that of Pulmicort® pMDI (budesonide 100 μg 2 actuations b.i.d., metered dose) and Symbicort Turbuhaler® (budesonide/formoterol 80/4.5 μg 2 actuations b.i.d., delivered dose) in children with asthma (SD-039- 0682). http://www.astrazenecaclinicaltrials.com/sites/133/ imagebank/typeArticleparam528362/SD-039-0682.pdf (accessed 26 November 2008).
36. Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. Pulmonary Pharmacology and Therapeutics. 2007/03/23 2008; Vol. 21, issue 1:152-9. [1094-5539: (Print)]
37. Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04334AM1) (COMPLETED). http:// clinicaltrials.gov/ct2/show/NCT00383240 (accessed 15 October 15 2012).
38. FDA. Clinical review of Dulera (NDA 22- 518). http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ UCM224593.pdf (accessed 3 October 2012):1-99.
39. 2-agonist). Chest 2009; Vol. 136, issue 4:8S.
40. Nathan R, Pearlman D, Nolte H, Nayak A. Efficacy and safety of combined medium-dose mometasone furoate/ formoterol (MF/F) in persistent asthmatics [Abstract]. Journal of Allergy and Clinical Immunology 2010; Vol. 125, issue 2 Suppl 1:AB195. [0091-6749]
41. Nathan R, Pearlman D, Nolte H, Nayak A. Efficacy and safety of combined mometasone furoate/formoterol 200/ 10mcg in persistent asthmatics [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22 2010:[E5489].
42. Nathan R, Pearlman D, Nolte H, Nayak A. Safety and tolerability of mometasone furoate/formoterol for persistent asthma subjects who previously were treated with mediumdose inhaled corticosteroids (alone or with a long-acting beta2-agonist) [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009; Miami, FL, USA.
43. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 mug combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy and Asthma Proceedings 2010; Vol. 31, issue 4:269-79.
44. Nathan RA, Pearlman D, Nolte H, Nayak A. Efficacy and safety of mometasone furoate and formoterol (MF/F) 200/10 mcg twice-daily administered via a pressurized metereddose inhaler in subjects 12 years of age and older with moderate-to-severe asthma [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010; Vol. 181, issue Meeting Abstracts:A5412.
45. Nathan RA, Weinstein SF, Nolte H. Lung function improvements over time with combined mometasone furoate/formoterol administered via a pressurized metereddose inhaler [Abstract]. Annals of Allergy, Asthma and Immunology 2010; Vol. 105, issue 5 Suppl.
46. AstraZeneca. A twelve-week, randomized, double-blind, double-dummy, placebo-controlled trial of SYMBICORT® (160/4.5 mcg) versus its mono-products (budesonide and formoterol) in adolescents (> 12 years of age) and adults with asthma, international (SD-039-0717). http:/ /www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0717.pdf (accessed 26 November 2008).
47. Baker J, Martin P, Parasuraman B. Patient satisfaction with budesonide and formoterol in one pressurized metereddose inhaler in patients with asthma. Chest 2007;132(4): 509b-510.
48. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 2006; Vol. 66, issue 17: 2235-54.
49. Noonan MJ, Eid NS, Uryniak T, O'Brien CD. Safety of once daily (qd) budesonide/formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children and adolescents with asthma previously stable on twice daily (bid) BUD/FM pMDI [Abstract]. American Thoracic Society International Conference; May 16-21, 2008; Toronto, Ontario, Canada. Abstract 711 [#K71].
50. Rosenwasser LJ, NoonanMJ,Martin P, O'Dowd L, O'Brien CD. Safety of budesonide and formoterol administered via one pressurized metered dose inhaler (budesonide/ formoterol pMDI) in patients (>12 years) with moderate to severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology 2007; Vol. 119, issue 1 Suppl:S5 [17].
51. Barnes PJ, O'Byrne PM, Rodriguez Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Treatment of mild persistent asthma with low doses of inhaled budesonide alone or in combination with formoterol. Thorax 2000;55 (Suppl 3):A4.
52. Grosser D, Smith B. Low-dose budesonide improved asthma control in mild asthma: adding formoterol improved control in corticosteroid-treated patients. ACP Journal Club. 2002;137(1):19.
53. Jonsson B, Berggren F, Svensson K, O'Byrne PM. An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-tomoderate persistent asthma. Respiratory Medicine 2004;98 (11):1146-54.
54. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide a costeffectiveness analysis. European Respiratory Journal 2001;18 (Suppl 33):517s.
55. Jönsson BG, Berggren FE, Svensson K, O'Byrne PM. Economic results of adding formoterol to budesonide in mild persistent asthma. European Respiratory Journal 2001; 18(Suppl 33):331s.
56. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom EVA, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine 2001; Vol. 164, issue 8:1392-7.
57. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Sandtröm T, Tattersfield AE, Runnerström EM, et al. Addition of formoterol Turbuhaler(r) to budesonide Tubuhaler(r) is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial. European Respiratory Journal 2001;18(Supp 33):330s.
58. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom EVA, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. American Journal of Respiratory and Critical Care Medicine 2001; Vol. 164, issue 8:1392-7.
59. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Lofdahl CGA, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. European Respiratory Journal 1999;14(5):1038-43.
60. Pauwels R. Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations. [Review]. Allergy 1998;53(42 Suppl):20-3.
61. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. New England Journal of Medicine. 1997/11/14 1997; Vol. 337, issue 20:1405-11. [0028-4793: (Print)]
62. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine 1999;160(2):594-9.
63. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [New England Journal of Medicine]. New England Journal of Medicine. 1997/11/14 1997; Vol. 337, issue 20:1405-11. [0028-4793: (Print)
64. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine 1999;160(2):594-9.
65. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [New England Journal of Medicine]. New England Journal of Medicine. 1997/11/14 1997; Vol. 337, issue 20:1405-11. [0028-4793: (Print)]
66. AstraZeneca. A 52-week, randomized, double-blind, single-dummy, parallel-group, multicenter Phase III study comparing the long-term safety of SYMBICORT® pMDI 160/4.5 mcg × 4 actuations twice daily to SYMBICORT® pMDI 160/4.5 mcg × 2 actuations twice daily and budesonide HFA pMDI 160 mcg × 4 actuations twice daily in adult and adolescent subjects with asthma (SD-039- 0728). http://www.astrazenecaclinicaltrials.com/sites/133/ imagebank/typeArticleparam528362/SD?039?0728.pdf (accessed 26 November 2008).
67. Lawrance R, Ambrose H, Goldman M. Effect of gly16arg beta2-adrenergic receptor variation on the long-term safety of formoterol (FM) in combination with budesonide (BUD) and of BUD alone, delivered via one pressurized metered-dose inhaler (pMDI) in patients with moderate to severe asthma [Abstract]. American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #420.
68. O'Brien CD, Peters SP, Prenner BM, Martin P. Long-term safety of budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) in asthma patients: adverse events and asthma exacerbations [Abstract]. American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L57.
69. O'Brien CD, Peters SP, Prenner BM, Martin P. Resource use with budesonide/formoterol pressurized metereddose inhaler (BUD/FM pMDI) versus BUD pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L58.
70. Peters SP, Prenner BM, Martin P, O'Brien CD. Long-term effects on lung function of budesonide (BUD) and formoterol (FM) in one pressurized metered-dose inhaler (BUD/FM pMDI) and BUD pMDI in patients with asthma [Abstract]. American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #K5.
71. Peters SP, Prenner BM,Mezzanotte WS,Martin P, O'Brien CD. Long-term safety and asthma control with budesonide/ formoterol versus budesonide pressurised metered-dose inhaler in asthma. Alllergy and Asthma Proceedings 2008;29: 1-18.
72. Prenner BM, Peters SP, Martin P, O'Brien CD. Long-term control of asthma symptoms with budesonide/formoterol pressurized metered-dose inhaler (BUD/FM pMDI) versus BUD pMDI [Abstract]. American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L67.
73. Prenner BM, Peters SP, Martin P, O'Brien CD. Safety pharmacodynamics (PD) of budesonide/formoterol (BUD/ FM) pMDI in asthma patients [Abstract]. American Thoracic Society International Conference; May 18-23, 2007; San Francisco, CA, USA. Poster #L66.
74. AstraZeneca. Efficacy and safety of Symbicort® (budesonide/formoterol 80/4.5 μg, 2 inhalations b.i.d.) compared to Pulmicort® (budesonide 100 mcg, 2 inhalations b.i.d.) and Pulmicort (budesonide 100 μg, 2 inhalations b.i.d.) plus Oxis® (formoterol 4.5 μg, 2 inhalations b.i.d.) all delivered via Turbuhaler® in steroid using asthmatic children: a double-blind, double-dummy, randomised, parallel-group, phase III, multicentre 12-week study (SD-039-0688). http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0688.pdf (accessed 26 November 2008).
75. Pohunek P, Kuna P, De Boeck K. Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma [Abstract]. European Respiratory Journal 2004;24(Suppl 48):379s.
76. Pohunek P, Kuna P, Jorup C, De Boeck K. Budesonide/ formoterol improves lung function compared with budesonide alone in children with asthma. Pediatric Allergy Immunology 2006; Vol. 17, issue 6:458-65.
77. Pohunek P, Matulka M, Rybnicek O, Kopriva F, Honomichlova H, Svobodova T. Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler compared with salmeterol Diskhaler in children with asthma. Pediatric Allergy Immunology 2004;15(1):32-9.
78. Price D, Dutchman D, Mawson A, Bodalia B, Duggan S, Todd P. Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose. Thorax. 2002/08/30 2002; Vol. 57, issue 9:791-8. [0040-6376: (Print)]
79. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics. 2002;20(3):183-94.
80. Price MJ, Sondhi S, Yan S, Nyth A, House K. Salmeterol/ fluticasone propionate combination inhaler is more cost effective than fluticasone propionate in patients with asthma. European Respiratory Society; Oct 9-13, 1999; Madrid, Spain. Poster #2459.
81. AstraZeneca. Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mg b.i.d.delivered dose) compared to budesonide Turbuhaler® (200 mg b.i.d. metered dose) in steroid-using asthmatic adolescent patients: a double-blind, double dummy,randomised, parallel group, phase III, multicentre study. (ATTAINSTUDY). http:/ /www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0714.pdf (accessed 14 November 2008).
82. AstraZeneca. A twelve-week, randomized, doubleblind, double-dummy trial of Symbicort® (40/4.5 mcg) versus its mono-products (budesonide and formoterol) in asthmatic children aged six to fifteen years. http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0718.pdf (accessed 14 November 2008).
83. Pearlman DS, Murphy KR, Uryniak T, O'Brien CD, Mezzanotte WS, Denver M. Safety of budesonide/ formoterol pressurized metered dose inhaler (BUD/FM pMDI) in children with asthma previously treated with inhaled corticosteroids (ICSs) [Abstract]. American Thoracic Society International Conference; May 16-21, 2008; Toronto, Ontario, Canada. Abstract #A710 (#K67).
84. AstraZeneca. A six-month, randomized, open-label safety study of SYMBICORT® (160/4.5 μg) compared to PULMICORT Turbuhaler® in asthmatic children aged 6 to 11 years. http://www.astrazenecaclinicaltrials.com/ sites/133/imagebank/typeArticleparam528362/SD-039- 0719.pdf (accessed 14 November 2008).
85. Berger WE, Bleecker ER, O'Dowd L,Miller CJ,Mezzanotte W. Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthma. Allergy and Asthma Proceedings 2010; Vol. 31, issue 1:49-59.
86. Berger WE, Leflein JG, Geller DE, Parasuraman B, Miller CJ, O'Brien CD, et al. The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. Allergy and Asthma Proceedings 2010; Vol. 31, issue 1:26-39.
87. Berger WE, Leflein JG, Uryniak T, O'Brien CD, O'Dowd L. Long-term efficacy and resource utilization after treatment with budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology 2008;121(2 Suppl 1):S8.
88. Leflein JG, Berger WE, Uryniak T, Vervaet P, O'Dowd L, O'Brien CD. Long-term safety and systemic effects of budesonide and formoterol administered via one pressurized metered-dose inhaler (pMDI) in children with asthma. Journal of Allergy and Clinical Immunology 2008;121(2 Suppl 1):S155.
89. O'Dowd L, Berger WE, Leflein JG, Uryniak T, Parasuraman B, O'Brien CD. Health-related quality of life (HRQL) and asthma control after long-term treatment with budesonide and formoterol administered via one pressurized metereddose inhaler (pMDI) compared with budesonide dry powder inhaler (DPI) alone in children with asthma. Journal of Allergy and Clinical Immunology 2008;121(2 Suppl 1):S152.
90. AstraZeneca. A twelve-week, randomized, doubleblind, double-dummy, active-controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma. http: //www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD?039?0725.pdf (accessed 18 November 2008).
91. Eid NS, Noonan MJ, Chipps B, Parasuraman B, Miller CJ, O'Brien CD. Once- vs twice-daily budesonide/formoterol in 6- to 15-year-old patients with stable asthma. Pediatrics 2010; Vol. 126, issue 3:e565-75.
92. AstraZeneca. A twelve-week, randomized, doubleblind, double-dummy, placebo- and active-controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma. http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0726.pdf (accessed 14 November 2008).
93. AstraZeneca. A 12-week, randomized, double-blind, double-dummy, multi-center,phase IV study comparing the efficacy and safety of SYMBICORT® pMDI160/4.5 μg × 2 actuations twice daily versus budesonide inhalation powderDPI 180 μg × 2 inhalations twice daily, in adult and adolescent (=12 years) African American subjects with asthma. http://www.astrazenecaclinicaltrials.com/ ?mshost800325/content/clinical-trials/resources/ pdf/D589BL00003 (accessed 19 October 2012). [D589BL00003]
94. Spector SL, CD OB, Uryniak T, Martin UJ. Safety and tolerability of a budesonide/formoterol (BUD/ FM) pressurized metered-dose inhaler (pMDI) in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Chest 2010; Vol. 138, issue 4:705A.
95. Spector SL, Martin UJ, Uryniak T, O'Brien CD. Budesonide/formoterol pressurized metered-dose inhaler versus budesonide: a randomized controlled trial in black patients with asthma. J Asthma. 2011/12/03 2012; Vol. 49, issue 1:70-7. [1532-4303: (Electronic)]
96. Spector SL, Martin UJ, Uryniak T, O'Brien CD. Effect of budesonide/formoterol pressurized metered-dose inhaler versus budesonide dry powder inhaler on asthma control in black adolescents and adults with moderate to severe persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology 2010; Vol. 105, issue 5 Suppl.
97. AstraZeneca. Efficacy and safety of budesonide/formoterol Turbuhaler® in a fixed combination in steroid-using asthmatic children-COMIC (SD-039-0353). http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0353.pdf (accessed 26 November 2008).
98. Tal A, Simon G, Vermeulen JH. Symbicort® Budesonide and formoterol in a single inhaler is effective and well tolerated in children with asthma. Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA, USA. Poster D29.
99. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatric Pulmonology 2002; Vol. 34, issue 5: 342-50.
100. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Rapid and sustained improvements in lung function and symptom control with budesonide/ formoterol in adolescent asthma. European Respiratory Journal 2001;18 (Suppl 33):494s.
101. Tal A, Simon G, Vermeulen JH, Petru V, Cobos N, Everard ML, et al. Symbicort budesonide and formoterol in a single inhaler is more effective that budesonide alone in children with asthma. International Paediatric Respiratory and Allergy Congress; April 1-4, 2001; Prague. Poster 84-5.
102. Tal A, Simon G, Vermeulen JH, Vit P, Cobos N, Everard ML, et al. The benefit of the new single inhaler product containing both budesonide and formoterol in asthmatic children. European Respiratory Journal 2000;16(Suppl 31): 384s.
103. Vermeulen JH, Simon G, Tal A. Symbicort® Budesonide and formoterol in a single inhaler improves lung function in asthmatic children aged 4-17 years. Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA, USA. Poster D29.
104. Schering-Plough. Effects of mometasone furoate/formoterol combination versus mometasone furoate alone in persistent asthmatics (Study P04431AM2) (COMPLETED). http:/ /clinicaltrials.gov/ct2/show/NCT00381485 (accessed 19 October 2012). [NCT00381485]
105. Weinstein S, Murphy K, Corren J, Nolte H, White M. Efficacy and safety of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment in subjects with severe persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology 2010; Vol. 125, issue 2 Suppl 1:AB196. [0091-6749]
106. Weinstein S, Murphy K, Corren J, Nolte H, White M. Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma. European Respiratory Society Annual Congress; September 18-22, 2010; Barcelona, Spain. Poster E5482.
107. Weinstein S, Murphy K, White M, Nolte H, Corren J. The safety and tolerability of high and medium doses of mometasone furoate/formoterol combination treatment in subjects with severe persistent asthma [Abstract]. Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology; 2009; Miami, FL, USA.
108. Weinstein S, Murphy K, White M, Nolte H, Corren J. Treatment of severe asthma with a new mometasone furoate and formoterol (MF/F) combination administered with a pressurized metered-dose inhaler device. American Journal of Respiratory and Critical Care Medicine 2010; Vol. 181, issue Meeting Abstracts:A5411.
109. Weinstein S, White M, Corren J, Nolte H. Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients [Abstract]. European Respiratory Society Annual Congress; September 12-16, 2009; Vienna, Austria. Poster E280.
110. Weinstein SF, Corren J, Murphy K, Nolte H, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 mug and 400/10 mug combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy and Asthma Proceedings 2010; Vol. 31, issue 4: 280-9.
111. Weinstein SF, White M, Corren J, Nolte H. Safety and tolerability of medium and high doses of mometasone furoate/formoterol (MF/F) combination treatment administered via a metered-dose inhaler (MDI), in severe asthma patients previously treated with high-dose inhaled corticosteroids (ICS). American Thoracic Society International Conference; May 15-20, 2009; San Diego, CA, USA. Poster #J53.
112. AstraZeneca. An efficacy study comparing SYMBICORT® pressurised metered dose inhaler (pMDI) with budesonide jydrofluoroalkanes (HFA) pMDI, in Hispanic subjects with ICS dependent asthma. http://clinicaltrials.gov/ct2/show/ study/NCT00419757?sect=X3015 (accessed 22 October 2012). [NCT00419757]
113. Zangrilli J, Mansfield LE, Uryniak T, O'Brien CD. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Annals of Allergy, Asthma, and Immunology 2011; Vol. 107:258-65.
114. AstraZeneca. Efficacy and safety of a fixed combination of budesonide/formoterol Turbuhaler® in inhaled steroid-using asthmatic adults. (SD-039-0349). http:// www.astrazenecaclinicaltrials.com/sites/133/imagebank/ typeArticleparam528362/SD-039-0349.pdf (accessed 26 November 2008).
115. Buhl R, Zetterstrom O, Mellem H, Perpina M, Hedman J, O'Neill S, et al. Improved asthma control with budesonide/formoterol via a single inhaler compared with budesonide alone, in moderate persistent asthma. European Respiratory Journal 2001;18(Suppl 33):48s.
116. Zetterstrom O, Buhl R, Mellem H. Efficacy and safety of Symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA.
117. Zetterstrom O, Buhl R,Mellem H, PerpinaM, Hedman J, O'Neill S, et al. Improved asthma control with budesonide/ formoterol in a single inhaler, compared with budesonide alone. European Respiratory Journal 2001; Vol. 18, issue 2: 262-8.
118. Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O'Neill S, et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal 2000;16(Suppl 31):455s. Abstract P3198.
119. Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O'Neill S, et al. The new single inhaler product containing both budesonide/formoterol improves asthma control in adults. European Respiratory Journal 2000;16(Supp 31): 455s. Abstract P3199.
120. Ankerst J, Persson G, Weibull E. Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma. Pulmonary Pharmacology Therapeutics 2003; Vol. 16, issue 3:147-51.
121. AstraZeneca. Efficacy safety of Symbicort Turbuhaler 160/4.5 μg twice daily Pulmicort Turbuhaler 200 μg twice daily + Theolong tablet 200 mg twice daily in Japanese asthmatic patients. clinicaltrials.gov 2005.
122. AstraZeneca. SHARE-symbicort and health economics in a real life evaluation. clinicaltrials.gov 2005.
123. AstraZeneca. SOLO-symbicort in the treatment of persistent asthma in adolescents adults. clinicaltrials.gov 2005.
124. AstraZeneca. STYLE-symbicort single inhaler therapy vs. conventional therapy in treatment of persistent asthma. clinicaltrials.gov 2005.
125. AstraZeneca. SYMPHONIE -a comparison of symbicort single inhaler and conventional best practice for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov 2005.
126. AstraZeneca. A comparison of the control of asthma inflammation provided by Symbicort turbuhaler 160/ 4.5 mcg/inhalation bid plus as-needed versus symbicort turbuhaler 320/9 ug/inhalation bid plus pulmicort turbuhaler 400mcg/dose bid plus terbutaline turbuhaler 0.4mg/inhalation as-needed. clinicaltrials.gov 2006.
127. AstraZeneca. MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. clinicaltrials.gov 2006.
128. AstraZeneca. SALTO-symbicort single inhaler therapy use in adolescent adults and adults with persistent asthma. clinicaltrials.gov 2006.
129. Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulmonary Pharmacology Therapeutics 2006; Vol. 19, issue 2:139-47.
130. Bateman ED, Bantje TA, Gomes MJ, Toumbis MG, Huber RM, Naya I, et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. American Journal of Respiratory Medicine 2003; Vol. 2, issue 3:275-81.
131. Bateman ED, Fairall L, Lombardi DM, English R. Budenoside/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respiratory Research 2006; Vol. 7:13.
132. Bodzenta-Lukaszyk A, Pulka G, Dymek A, Bumbacea D, McIver T, Schwab B, et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respiratory Medicine 2011; Vol. 105, issue 5:674-82.
133. Bouros D, Bachlitzanakis N, Kottakis J, Pfister P, Polychronopoulos V, Papadakis E, et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. European Respiratory Journal 1999; Vol. 14, issue 3:627-32.
134. Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN, et al. The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing. Current Medical Research Opinion 2004; Vol. 20, issue 8:1209-20.
135. Bumbacea D, Dymek A, Mansikka H. Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently: a randomised controlled trial [Abstract]. Thorax 2010; Vol. 65, issue Suppl 4:P16.
136. Burgess C, AysonM, Rajasingham S, Crane J, Della Cioppa G, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. European Journal of Clinical Pharmacology 1998; Vol. 54, issue 2:141-7.
137. Canonica GW, Castellani P, Cazzola M, Fabbri LM, Fogliani V, Mangrella M, et al. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulmonary Pharmacology Therapeutics 2004; Vol. 17, issue 4:239-47.
138. Ceylan E, Mehmet G, Sahin A. Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control. Respiration 2004; Vol. 71, issue 6:594-601.
139. Dhillon S, Keating GM. Beclometasone dipropionate/ formoterol in an HFA-propelled pressurised metered-dose inhaler. Drugs 2006; Vol. 66, issue 11:1475-83.
140. FitzGerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till MD, et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. Journal of Allergy Clinical Immunology 1999; Vol. 103, issue 3 I:427-35.
141. FitzGerald JM, Sears MR, Boulet LP, Becker AB, McIvor AR, Ernst P, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Canadian Respiratory Journal 2003; Vol. 10, issue 8:427-34.
142. Haahtela T, Tamminen K, Malmberg LP, Zetterstrom O, Karjalainen J, Yla-Outinen H, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. European Respiratory Journal 2006; Vol. 28, issue 4: 748-55.
143. Ind PW, Haughney J, Price D, Rosen JP, Kennelly J. Adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Respiratory Medicine 2004; Vol. 98, issue 5:464-75.
144. Jakopovic M, Pavicic F, Redzepi G, Plestina S, Jankovic M, Franic Z, et al. Efficacy and safety of budesonide/ formeterol combination therapy in asthma patients. Collegium Antropologicum 2009; Vol. 33, issue 2:587-91. [0350-6134]
145. Kozlik-Feldmann R, von Berg A, Berdel D, Reinhardt D. Long-term effects of formoterol and salbutamol on bronchial hyperreactivity and beta-adrenoceptor density on lymphocytes in children with bronchial asthma. European Journal of Medical Research 1996; Vol. 1, issue 10:465-70.
146. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; Vol. 123, issue 5:1480-7.
147. Lemanske RF, Jr, Mauger DT, Sorkness CA, Pharm D, Jackson DJ, Boehmer SJ, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. New England Journal of Medicine 2010; Vol. 362, issue 11:975-85.
148. Leuppi FD, Salzberg M, Meyer L, Bucher SE, Nief M, Brutsche MH, et al. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing. Swiss Medical Weekly 2003; Vol. 133, issue 21-22:302-9.
149. Lötvall J, Langley S, Woodcock A. Inhaled steroid/longacting beta2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respiratory Research 2006; Vol. 7:110.
150. Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al. Maintenance plus reliever budesonide/ formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Current Medical Research and Opinion 2006; Vol. 22, issue 5: 809-21.
151. Maspero JF, Nolte H, Cherrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. Journal of Asthma 2010; Vol. 47, issue 10:1106-15.
152. Mitchell C, Jenkins C, Scicchitano R, Rubinfeld A, Kottakis J. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmonary Pharmacology and Therapeutics 2003; Vol. 16, issue 5: 299-306.
153. Molimard M, Bourcereau J, Le Gros V, Bourdeix I, Leynadier F, Duroux P, et al. Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respiratory Medicine 2001; Vol. 95, issue 1:64-70.
154. Nayak A, LaForce C, Nathan RA, Nolte H, Weinstein SF. Mometasone furoate/formoterol administered via a pressurized metered-dose inhaler improves proportions of saba-free days and nights in subjects with persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology 2010; 105:5 Suppl.
155. Novartis. A 12-month multicenter, randomized, doubleblind, double-dummy trial to examine the long-term tolerability of formoterol 10μg via the multiple dose dry powder inhaler (MDDPI), both as twice daily maintenance therapy and as on-demand use in addition to maintenance in patients with persistent asthma. http:// pharma.us.novartis.com/.
156. O'Byrne PM, BisgaardH,Godard PP, PistolesiM, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.[see comment]. American Journal of Respiratory Critical Care Medicine 2005; Vol. 171, issue 2:129-36.
157. Ohta K, Adachi M. Efficacy and safety of budesonide/ formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma [Abstract]. European Respiratory Society Annual Congress; October 4-8, 2008; Berlin, Germany. Poster 3626.
158. Overbeek SE, Mulder PG, Baelemans SM, Hoogsteden HC, Prins JB. Formoterol added to low dose budesonide has no additional anti-inflammatory effect in asthmatic patients. Chest 2005;128:1121-7.
159. Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM, Zarkovic J, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. European Respiratory Journal 2007; Vol. 29, issue 4:682-9.
160. Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. European Respiratory Journal 2003; Vol. 22, issue 5:787-94.
161. Peters SP, Rosenwasser LJ, Vervaet P, O'Brien CD. Cardiac safety of budesonide (BUD)/formoterol (FM) pressurized metered dose inhaler (pMDI) pooled data from clinical studies of children, adolescents and adults with asthma [Abstract]. Journal of Allergy and Clinical Immunology 2008; Vol. 121, issue 2 Suppl 1:S155 [595].
162. Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. Journal of Asthma 2003; Vol. 40, issue 5:505-14.
163. Pohl WR, Vetter N, Zwick H, Hrubos W. Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study. Respiratory Medicine 2006; Vol. 100, issue 3:551-60.
164. Rabe KF, Pizzichini E, Stallberg B, Romero S, Balanzat AM, Atienza T, et al. Budisonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; Vol. 129, issue 2:246-56.
165. Rosenhall L, Heinig JH, Lindqvist A, Leegaard J, Stahl E, Bergqvist PB. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. International Journal of Clinical Practice. 2002; Vol. 56, issue 6:427-33.
166. Rosenhall L, Borg S, Andersson HF, Ericsson K. Budesonide/formoterol in a single inhaler (Symbicort) reduces healthcare costs compared with separate inhalers in the treatment of asthma over 12 months. International Journal of Clinical Practice 2003; Vol. 57, issue 8:662-7.
167. Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Stahl E, et al. One-year safety and efficacy of budesonide/ formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma. Respiratory Medicine 2003; Vol. 97, issue 6:702-8.
168. Rosenwasser LJ, Peters SP, Vervaet P, O'Brien CD. Tolerability of budesonide (BUD)/formoterol (FM) pressurized metered dose inhaler (pMDI) pooled adverse event (AE) data from clinical studies of children, adolescents and adults with asthma [Abstract]. Journal of Allergy and Clinical Immunology 2008; Vol. 121, issue 2 Suppl 1:S154 [591].
169. Saito T, Hasunuma T. Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler in Japanese patients with asthma: phase III study results. American Journal of Respiratory and Critical Care Medicine 2011;183(Meeting Abstracts):A4489.
170. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centann S, et al. Efficacy and safety of budesonide/ formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research Opinion 2004; Vol. 20, issue 9:1403-18.
171. Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulmonary Pharmacology and Therapeutics. 2006/10/19 2007; Vol. 20, issue 6:691-700. [1094-5539: (Print)]
172. van der Molen T, Postma DS, Turner MO, Jong BM, Malo JL, Chapman K, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997; Vol. 52, issue 6:535-9.
173. Villa J, Kuna P, Egner J, Brander R. A 6-month comparison of the safety profiles of formoterol (Oxis®) turbuhaler® as needed and terbutaline (Bricanyl®) turbuhaler® as needed in asthmatic children on anti-inflammatory medication [abstract]. American Journal of Respiratory and Critical Care Medicine 2002; Vol. 165, issue 8 Suppl:A746.
174. Von Berg A, Papageorgiou Saxoni F, Wille S, Carrillo T, Kattamis C, Helms PJ. Efficacy and tolerability of formoterol turbuhaler in children. International Journal of Clinical Practice 2003; Vol. 57, issue 10:852-6.
175. Weinstein S, Nathan RA, Meltzer E, Nolte H, Maspero J. Treatment of persistent asthma with mometasone furoate/ formoterol combination therapy is associated with a low incidence of oral candidiasis and dysphonia [Abstract]. Congress of the Asian Pacific Society of Respirology; 2010; Manila, Philippines.
176. White M, Meltzer EO, Nathan RA, Nolte H. Improved asthma control with mometasone furoate/formoterol: a new combination treatment for persistent asthma [Abstract]. Annals of Allergy, Asthma and Immunology 2010; Vol. 105, issue 5 Suppl.
177. Worth H. DESOLO-SiT Peri-Launch: a comparison of symbicort single inhaler therapy and conventional best practice for the treatment of persistent asthma in adults. clinicaltrials.gov (accessed 3rd September 2008).
178. Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O'Neill S, et al. Efficacy and safety of a new single inhaler product containing both budesonide and formoterol in adult asthma. European Respiratory Journal 2000; Vol. 16, issue Suppl 31:455s. Abstract P3198.
179. Zetterstrom O, Buhl R, Mellem H. Efficacy and safety of symbicort® budesonide and formoterol in a single inhaler in adults with asthma. Annual Thoracic Society 97th International Conference; May 18-23, 2001; San Francisco CA, USA.
180. AstraZeneca. A 6 month safety study comparing Symbicort with inhaled corticosteroid only in asthmatic adults and adolescents. ClinicalTrials.gov 2012 (accessed June 2012).
181. Merck. A serious asthma outcome study with mometasone furoate/formoterol versus mometasone furoate in asthmatics 12 years and over (P06241 AM3) (SPIRO). ClinicalTrials.gov (accessed June 2012).
182. Altman DG, Bland JM. Statistics Notes: Interaction revisited: the difference between two estimates. BMJ 2003; 326(7382):219.
183. Anderson GP. Current issues with beta(2)-adrenoceptor agonists-Pharmacology and molecular and cellular mechanisms. Clinical Reviews in Allergy Immunology 2006; Vol. 31, issue 2-3:119-30.
184. Arnold JMO, O'Connor PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG. Effects of the beta-2- adrenoceptor antagonist ici-118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. British Journal of Clinical Pharmacology 1985; Vol. 19, issue 5:619-30.
185. Barnes PJ. Beta-adrenoceptors on smooth-muscle, nerves and inflammatory cells. Life Sciences 1993; Vol. 52, issue 26:2101-9.
186. Barnes PJ. Beta-adrenergic receptors and their regulation. American Journal of Respiratory and Critical Care Medicine 1995; Vol. 152, issue 3:838-60.
187. Beach JR, Young CL, Stenton SC, Avery AJ, Walters EH, Hendrick DJ. A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholineinduced bronchoconstriction. Pulmonary Pharmacology 1992;5(2):133-5.
188. Bennett JA, Smyth ET, Pavord ID, Wilding PJ, Tattersfield AE. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; Vol. 49, issue 8:771-4.
189. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Statistics in Medicine 2007;26(1):53-77.
190. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta-2-receptor stimulation by circulating epinephrine. New England Journal of Medicine 1983; Vol. 309, issue 23:1414-9.
191. Burgess CD, Windom HH, Pearce N, Marshall S, Beasley R, Siebers RWL, et al. Lack of evidence for beta-2 receptor selectivity a study of metaproterenol, fenoterol, isoproterenol, and epinephrine in patients with asthma. American Review of Respiratory Disease 1991; Vol. 143, issue 2:444-6.
192. Burggraaf J, Westendorp RGJ, in't Veen J, Schoemaker RC, Sterk PJ, Cohen AF, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; Vol. 56, issue 7:567-9.
193. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/ 14651858.CD006363.pub2]
194. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/ 14651858.CD006902.pub2]
195. Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006923.pub3; CD006923]
196. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2012, issue 10:Art. No.: CD010005. [DOI: 10.1002/14651858.CD010005.pub2]
197. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. The New England Journal of Medicine 2011;364(26):2473-5.
198. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; Vol. 342, issue 8875:833-7.
199. Collins JM, McDevitt DG, Shanks RG, Swanton JG. Cardio-toxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1969; Vol. 36, issue 1:35-45.
200. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, Kwong T, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83 case-control study. Lancet 1989; Vol. 1, issue 8644:917-22.
201. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/ 14651858.CD005533.pub2]
202. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/ 14651858.CD003137.pub4]
203. Giembycz MA, Newton R. Beyond the dogma: novel ß2- adrenoceptor signalling in the airways. European Respiratory Journal 2006;27(6):1286-306.
204. Grainger J, Woodman K, Pearce N, Crane J, Burgess C, Keane A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7 a further case-control study. Thorax 1991; Vol. 46, issue 2:105-11.
205. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000; Vol. 55, issue 8:650-6.
206. Hall JA, Petch MC, Brown MJ. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2- adrenoceptors in the human-heart. Circulation Research 1989; Vol. 65, issue 3:546-53.
207. Hanania NA, Sharfkhaneh A, Barber R, Dickey BF. betaagonist intrinsic efficacy-Measurement and clinical significance. American Journal of Respiratory and Critical Care Medicine 2002; Vol. 165, issue 10:1353-8.
208. Hanania NA, Moore RH, Zimmerman JL, Miller CT, Bag R, Sharafkhaneh A, et al. The role of intrinsic efficacy in determining response to beta(2)-agonist in acute severe asthma. Respiratory Medicine 2007; Vol. 101, issue 5: 1007-14.
209. Hancox RJ, Aldridge RE, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, et al. Tolerance to betaagonists during acute bronchoconstriction. European Respiratory Journal 1999; Vol. 14, issue 2:283-7.
210. Hancox RJ. Interactions between corticosteroids and beta2- agonists. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2-3:231-46. [(Print)]
211. Haney S, Hancox RJ. Recovery from bronchoconstriction and bronchodilator tolerance. Clinical Reviews in Allergy and Immunology 2006; Vol. 31, issue 2-3:181-96.
212. Harvey JE, Tattersfield AE. Airway response to salbutamol - effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax 1982; Vol. 37, issue 4: 280-7.
213. Expert Working Group (Efficacy) of theInternational Conference on Harmonisation of Technical Requirements for Registrationof Pharmaceuticals for Human Use (ICH). Clinical safety data management: Definitions and standards for expedited reporting. www.fda.gov/cder/guidance/ iche2a.pdf.
214. Jaeschke R, O'Byrne PM, Nair P, Mejza F, Le niak W, Brozek J, et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej 2008; Vol. 118, issue 11:627-35.
215. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lesniak W, Brozek J, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. America Journal of Respiratory and Critical Care Medicine 2008; Vol. 178, issue 10:1009-16.
216. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. European Respiratory Journal 2001; Vol. 17, issue 3:368-73.
217. Lee DKC, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. British Journal of Clinical Pharmacology 2003; Vol. 56, issue 5:494-500.
218. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high-dose inhaled salbutamol in asthmatics. American Review of Respiratory Disease 1989; Vol. 140, issue 3:586-92.
219. Lipworth BJ, McDevitt DG. Inhaled beta-2-adrenoceptor agonists in asthma help or hindrance. British Journal of Clinical Pharmacology 1992; Vol. 33, issue 2:129-38.
220. Lipworth BJ. Airway sub-sensitivity with long-acting beta 2-agonists: Is there cause for concern?. Drug Safety 1997;16 (5):295-308.
221. Lipworth BJ, Aziz I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; Vol. 117, issue 1:156-62.
222. McDevitt DG, Shanks RG, Swanton JG. Further observations on cardiotoxicity of isoprenaline during hypoxia. British Journal of Pharmacology 1974; Vol. 50, issue 3:335-44.
223. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved longacting 2-adrenergic receptor agonists. Pediatrics 2011;128 (5):e1147-54.
224. Morrison KJ, Gao Y, Vanhoutte PM. Beta-adrenoceptors and the epithelial layer in airways. Life Sciences 1993; Vol. 52, issue 26:2123-30.
225. Nelson HS, Raine D, Doner HC, Posey WC. Subsensitivity to bronchodilator action of albuterol produced by chronic administration. American Review of Respiratory Disease 1977; Vol. 116, issue 5:871-8.
226. Ni ChroininM,Greenstone I, Lasserson TJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD005307.pub2]
227. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/ 14651858.CD005535; CD005535]
228. Novartis. Foradil (formoterol fumarate inhalation powder). FDA Advisory Committee Meeting for the safety of long-acting beta2 -agonists for the treatment of asthma in adults and children (December 10-11, 2008). http:// www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1- 02-Novartis.pdf (accessed 8 January 2009).
229. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. American Journal of Respiratory and Critical Care Medicine 1999; Vol. 160, issue 1:244-9.
230. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; Vol. 45, issue 3:170-5.
231. Pearce N. Adverse Reactions: The Fenoterol Story. 1. Auckland: Auckland University Press, 2007:215. [9781869403744]
232. Sears M, Rea H, Rothwell R, O'Donnell T, Holst P, Gillies A, et al. Asthma mortality: comparison between New Zealand and England. British Medical Journal 1986;293 (6558):1342-5.
233. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial-asthma. Lancet 1990; Vol. 336, issue 8728: 1391-6.
234. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting-agonists: A review of formoterol safety data from asthma clinical trials. European Respiratory Journal 2008: 09031936.00145006.
235. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol. Chest 2006;129:15-26.
236. Castle W, Fuller R, Hall J. Serevent nationwide surveillance study:Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. British Medical Journal 1993;306:1034-7.
237. Speizer FE, Doll R, Heaf P. Observations on recent increase in mortality from asthma. British Medical Journal 1968; Vol. 1, issue 5588:335-40.
238. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004/04/30 2004; Vol. 23, issue 9:1351-75. [0277-6715: (Print)]
239. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta(2) agonists. Thorax 2001; Vol. 56, issue 7: 529-35.
240. vanNoord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action. European Respiratory Journal 1996; Vol. 9, issue 8:1684-8.
241. Walters EH, Walters JAE, Gibson PW. Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/ 14651858.CD003901]
242. Walters EH, Gibson PG, Lasserson TJ, Walters JAE. Longacting beta2-agonists for stable chronic asthma (Cochrane Review). Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001385.pub2]
243. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatics development of subsensitivity with longterm administration. Journal of Allergy and Clinical Immunology 1982; Vol. 70, issue 6:417-22.
244. Wilson JD, Sutherland DC, Thomas AC. Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma. Lancet 1981; Vol. 1, issue 8232: 1235-7.
245. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; Vol. 336, issue 8728:1396-9.
246. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta(2)-agonist. American Journal of Respiratory and Critical Care Medicine 1996; Vol. 154, issue 6:1603-7.
247. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/ 14651858.CD006924.pub2]